Biotech Microcaps Explode: PHIO Soars 143%, THAR Jumps 129%
By ATTN Desk · Editorial oversight: Sean Han
Daily Market Recap: November 3, 2025
Introduction
U.S. equities saw a broad‐based rally on Monday, driven primarily by clinical‐stage biotechnology and small‐cap momentum plays. Biotech names dominated the leaderboard, with several microcaps more than doubling on trial updates, regulatory cues and corporate filings. Heavy trading volumes accompanied the surge, underscoring renewed investor appetite for speculative, low‐float stories.
Price and Volume Table
| Ticker | ATTN Price | Current Price | Volume | Price Change % |
|---|---|---|---|---|
| EZGO | 0.1092 | 0.1752 | 107,602,766 | 60.50% |
| ALPS | 0.9067 | 1.4300 | 2,653,497 | 57.66% |
| RNTX | 1.2750 | 1.7700 | 22,579,042 | 38.85% |
| MSPR | 0.2426 | 0.5232 | 448,742,656 | 115.71% |
| PHIO | 0.7639 | 1.8600 | 83,214,480 | 143.58% |
| NCRA | 1.5359 | 1.9700 | 17,687,181 | 28.34% |
| KVUE | 15.2100 | 16.1550 | 115,357,266 | 6.23% |
| BHVN | 13.0390 | 14.8600 | 2,594,134 | 14.00% |
| CRBU | 1.6410 | 2.4350 | 31,044,237 | 48.32% |
| ZOOZ | 0.6005 | 0.7495 | 6,761,704 | 24.88% |
| CLPT | 15.0280 | 18.9999 | 3,000,885 | 26.41% |
| THAR | 1.3966 | 3.1950 | 29,068,903 | 128.90% |
| AREC | 3.1598 | 4.0092 | 32,829,565 | 26.86% |
| FLYE | 0.3448 | 0.5000 | 2,184,363 | 44.98% |
| RAY | 0.1470 | 0.2199 | 53,087,597 | 49.57% |
| TCRX | 0.9217 | 1.2400 | 3,723,863 | 34.55% |
| TERN | 11.0060 | 14.0200 | 20,937,102 | 27.41% |
| FGL | 0.2566 | 0.4037 | 21,549,111 | 57.42% |
| NCEL | 4.4980 | 5.2500 | 245,482 | 16.80% |
| NOMA | 6.0610 | 11.5900 | 175,986 | 91.34% |
Biotech Rally by Samantha Sophia
Market Analysis
Monday’s session was defined by outsized moves in speculative biotech and small‐cap issues. The Nasdaq Biotechnology Index outperformed broader benchmarks as investors rotated toward high‐beta, data‐driven names. Volume spiked across many tickers—in particular MSPR, EZGO and PHIO—suggesting heavy participation from retail and momentum‐oriented traders.
Clinical‐stage firms led the pack after trial updates and regulatory affirmations. PHIO surged 143.6% on encouraging PH-762 data and a supportive virtual roadshow, while THAR rallied 128.9% following an FDA 505(b)(2) pathway nod and disclosures of a BlackRock stake. MSPR climbed 115.7% amid a reverse split and warrant registration, echoing a broader thematic interest in capital raises. Outside biotech, NOMA jumped 91.3% post‐direct listing volatility, and EV shuttle provider EZGO advanced 60.5% on management changes and an equity plan.
By contrast, mid‐caps and blue-chips displayed more modest gains, reflecting a bifurcated market in which risk assets outperformed defensives. Sector rotation appeared limited, with technology and healthcare names driving most intraday breadth.
Notable Movers and Volume Surges
- PHIO led with the largest percentage gain and delivered the second‐highest volume behind MSPR, highlighting strong speculative interest in immuno‐oncology data.
- MSPR recorded the day’s highest volume (448.7 million shares) after its 1-for-7 reverse split and new offering registration.
- THAR and EZGO each saw turnover exceeding 29 million and 107 million shares, respectively, on regulatory news and corporate filings.
- NOMA and FGL also featured multi-day highs in volume, underscoring the prevailing appetite for thinly traded, high‐volatility stocks.
TL;DR
• Clinical‐stage biotech and small caps powered Monday’s gains.
• PHIO (+143.6%), THAR (+128.9%) and MSPR (+115.7%) led on data releases, FDA cues and corporate actions.
• EZGO, NOMA and FGL also saw triple-digit percentage advances on management changes and listing dynamics.
• Heavy volumes across speculative names point to continued momentum trading in low-float issues.
• Broader indices posted modest gains as investors favored high-beta, event-driven opportunities.